CEO Update | Monday 13 July 2020

I was delighted to attend the launch of a $1 billion Antimicrobial Resistance (AMR) Action Fund, which aims to support vital research which hopes to bring two to four new antibiotics to market by 2030. The fund will be available to UK small and medium sized companies seeking to develop new antibiotics, those in this field will be able to apply this autumn. Find out more about the fund here.

An Essential First Step to Market Access for Medicines

UK PharmaScan is a database of information on new medicines, indications and formulations in the pharmaceutical pipeline. It is the primary source of information used by all of the UK’s national horizon scanning organisations and NHS England to enable early engagement in planning and preparing the NHS for the introduction of new medicines and to support faster NHS adoption.

BIA welcomes Global AMR Action Fund to tackle antimicrobial resistance 

Steve Bates OBE, Chief Executive of the BIA said: “Antimicrobial resistance (AMR) is one of the key global challenges of our times. Despite being a global health (and BIA) policy focus for years, no market solution has yet delivered the incentives needed to make novel antibiotic development an attractive investment prospect.

Guest Blog|In2scienceUK Covid-19 response

The BIA is a supporter of the the award winning charity In2scienceUK. This year In2scienceUK has launched an ambitious Covid-19 response allowing young people across the country to gain essential skills, role models and knowledge on STEM Skills and careers. In this blog, their Development Officer Luke McKelvey tells us about the programme and how BIA members can get involved.

Horizon Discovery introduces Cas9 and dCas9-VPR stable cell lines to simplify and accelerate CRISPR gene editing workflows

QC-validated cell lines optimized to work alongside Horizon’s Edit-R predesigned sgRNA products and DharmaFECT transfection reagents

CTI Named #1 CRO in the World for Quality at 2020 Clinical and Research Excellence Awards

CTI Clinical Trial and Consulting Services (CTI), a multi-national, privately held, full-service contract research organization (CRO) was named Champion in multiple categories of the 2020 CRO Leadership Awards, and was the only CRO named as Champion in the Quality category.

KQ Labs opens applications for early stage data-driven health start-ups for its third annual accelerator programme and announces LifeArc as a strategic partner

KQ Labs is now accepting applications for its third cohort of companies. Early stage data-driven health companies are invited to apply

Mogrify adds Dr. Lorenz Mayr to Board of Directors and Scientific Advisory Board

Mogrify Ltd (Mogrify®), a UK biotechnology company aiming to transform the development of cell therapies by the systematic discovery of novel cell conversions, today announced the appointment of Lorenz Mayr, PhD, to the Board of Directors and the Scientific Advisory Board (SAB).

CEO Update|Monday 06 July

It was great to see NHS England agree a deal with BIA member Vertex last week, to enable their new cystic fibrosis drug combination Kaftrio available to NHS patients. This is brilliant news for the cystic fibrosis community with nine in 10 patients set to benefit from this life-transforming medicine.

Practical completion achieved for Bellhouse Building at The Oxford Science Park

The Oxford Science Park (TOSP), one of the UK's leading parks for science and technology companies, is pleased to announce that its newest facility, the 30,000 sq ft Bellhouse Building, has reached practical completion.